A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss (SCALP2)
A 6-month Phase 3, Multicenter, Prospective, Randomized, Double-Blind, Vehicle-Controlled Study, to Evaluate the Efficacy and Safety of Topically Applied Clascoterone Solution for the Treatment of Androgenetic Alopecia in Males, Followed by a 6-month Single-Blind Treatment With Clascoterone or Vehicle Solution
In the register
The register attaches this trial to Clascoterone (Breezula) (Cosmo Pharmaceuticals), currently at “Phase 3” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Completed
- Declared phase
- Phase 3
- Sponsor
- Cassiopea SpA
- Participants (registry)
- 762
- Start
- August 2023
- Primary completion
- July 2025
- Study completion
- July 2025
- Last registry update
- December 2025
- Countries
- United States, Germany, Poland
Conditions studied: Alopecia, Androgenetic
Interventions: Clascoterone 5% solution, CB-03-01 5% solution, Vehicle solution, Vehicle
Other trials of Clascoterone (Breezula)
A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss
A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.